A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Cornell University
Wake Forest School of Medicine
Information provided by (Responsible Party):
Anthony J Viera, MD, MPH, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01658657
First received: July 31, 2012
Last updated: April 7, 2014
Last verified: April 2014

July 31, 2012
April 7, 2014
October 2012
June 2014   (final data collection date for primary outcome measure)
Blood pressure control, as defined as office BP measurement of <140 mmHg systolic and <90 mmHg diastolic [ Time Frame: 4 months ] [ Designated as safety issue: No ]
At each study visit (approximately every 30 days), participants' BP will be checked. If BP is controlled (<140mmHG systolic and <90mmHG diastolic), then current medication will continue. If BP is uncontrolled, medication will be revised every 30 days (up to 120) until BP control is achieved.
Same as current
Complete list of historical versions of study NCT01658657 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

The purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment. Plasma renin is an enzyme in your blood that can be measured to determine your hypertension subtype. Once the subtype is known, doctors can prescribe specific medications to target your specific hypertension subtype. This study will investigate whether targeting the specific hypertension subtype helps to achieve blood pressure control sooner and with fewer medications compared to a standard fixed dose combination therapy.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hypertension
  • Plasma Renin Activity
  • Drug: Hydrochlorothiazide
  • Drug: Lisinopril
  • Drug: Amlodipine
  • Drug: metoprolol
  • Drug: lisinopril/hydrochlorothiazide
  • Experimental: PRA-guided therapy
    Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
    Interventions:
    • Drug: Hydrochlorothiazide
    • Drug: Lisinopril
    • Drug: Amlodipine
    • Drug: metoprolol
  • Active Comparator: Fixed-dose combination treatment-guided therapy
    Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
    Interventions:
    • Drug: Amlodipine
    • Drug: metoprolol
    • Drug: lisinopril/hydrochlorothiazide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
24
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Systolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 150 mmHg, or diastolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 95 mmHg
  • Not currently taking BP-lowering medication
  • Clinician recommends pharmacologic treatment
  • Willing to make necessary study visits
  • Able to be contacted by phone
  • Has a primary care clinician
  • At least 18 years old

Exclusion Criteria:

  • Known secondary cause of hypertension
  • Pregnancy
  • Known diabetes, coronary artery disease or renal disease
  • Known sulfonamide allergy or history of gout
  • Participant's clinician recommends he/she not enroll
  • Hyponatremia, hypokalemia, hypernatremia, or hyperglycemia at baseline visit
  • Baseline visit systolic visit BP average < 140 mmHg and diastolic BP average < 90 mm Hg
  • Resting heart rate < 55 beats per minute
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01658657
12-1133
No
Anthony J Viera, MD, MPH, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
  • Cornell University
  • Wake Forest School of Medicine
Principal Investigator: Anthony Viera, MD, MPH Distinguished Associate Professor, Family Medicine
University of North Carolina, Chapel Hill
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP